- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06740058
Bladder Wall Thickness in Symptomatic Urinary Stress Incontinence and Its Correlation with Urodynamics Results (BWT-IUS)
December 17, 2024 updated by: Stefano Salvatore, IRCCS San Raffaele
Bladder Wall Thickness in Symptomatic Urinary Stress Incontinence and Its Correlation with Urodynamics Results. a Retrospective and Prospective Observational Study
This clinical study aims to assess the utility of ultrasonographic bladder wall thickness (BWT) measurement in patients suffering from symptomatic stress urinary incontinence (SUI).
SUI is a condition characterized by involuntary leakage of urine during activities that increase intra-abdominal pressure and represents a very frequent disorder impacting women's quality of life.
To diagnose SUI more accurately and especially before surgical treatment, patients undergo invasive urodynamic examination.
This examination allows us to objectify the presence of any bladder dysfunction and, in particular, to evaluate the presence of detrusor overactivity.
Detrusor overactivity is defined as any occurrence of detrusor contraction(s) during filing cystometry.
These contractions, which may be spontaneous or provoked, produce a waveform on the cystogram, of variable duration and amplitude and may cause or not urgency symptoms.
In absence of any urodynamic detrusor overactivity, the patient may be diagnosed with pure SUI.
This is essential to assess before surgical treatment to avoid worsening of symptoms and to decide whether to treat the patient with concomitant pharmacological treatment.
On the contrary, ultrasonography offers a non-invasive and accessible approach to evaluate bladder function.
This study will involve a cohort of patients with SUI, who will undergo ultrasonographic assessment of BWT and preoperative urodynamic assessment.
The objective is to determine whether BWT correlates with the urodynamics results and whether it can predict the presence or absence of detrusor overactivity and confirm the pure stress urinary incontinence
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
60
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Vittoria Benini
- Phone Number: 00393937126100
- Email: benini.vittoria@hsr.it
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with pure or prevalent stress urinary incontinence who undergo invasive urodynamic examination
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study.
- Women aged > 18 y.o.
- Women symptomatic for pure or predominant stress incontinence attending the urogynecology outpatient clinic at our institution.
- Patients undergoing urogynecological standard evaluation for their symptoms, including outpatient gynecological visit and a transvaginal ultrasound.
- Patients undergoing invasive urodynamic examination for objective assessment of their symptoms or in preparation for possible anti-incontinence surgery.
Exclusion Criteria:
- Patients with pure or predominant OAB symptomatology
- Current use of antimuscarinic agents or beta3-agonists (for example Mirabegron)
- Presence of urological or gynecological cancer.
- Patients with previous anti-incontinence surgery.
- Patients with pelvic organ prolapse > II stage.
- Patients with chronic bladder retention.
- Patients with neurological diseases that may affect bladder function and urodynamic results.
- Participants unwilling or unable to give informed consent for participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Bladder wall thickness in millimeters (mm) in two different bladder points (dome and trigone) in patients with or without detrusor overactivity at urodynamic assessment
Time Frame: From enrollment to the urodynamic examination that will be performed with 6 months from baseline visit
|
From enrollment to the urodynamic examination that will be performed with 6 months from baseline visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2025
Primary Completion (Estimated)
February 1, 2026
Study Completion (Estimated)
February 1, 2026
Study Registration Dates
First Submitted
December 13, 2024
First Submitted That Met QC Criteria
December 17, 2024
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
December 17, 2024
Last Verified
December 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BWT-IUS
Drug and device information, study documents
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.